

9206-1,²³ JCOG 9206-2,²⁴ and National Surgical Adjuvant Study Group for Gastric Cancer (N-SAS-GC)²⁵ studies have evaluated postoperative adjuvant chemotherapy after D2 surgery in Japan. These studies involved only about 200 patients each. Although the results of the N-SAS-GC study showed that adjuvant chemotherapy with uracil-tegafur (an oral fluoropyrimidine prodrug) was effective, confirmatory studies were needed. Because of the high incidence of gastric cancer in Japan, an effective regimen for adjuvant chemotherapy is particularly important there. Our decision to perform this phase 3 trial of S-1 in patients who underwent curative resection was based on the results of previous clinical trials showing that S-1 alone is effective for the treatment of advanced gastric cancer and may therefore be useful as adjuvant chemotherapy.

More than 100 centers located throughout Japan participated in our trial. To ensure a uniform level of surgical quality, the participating centers were selected from among hospitals performing at least 100 operations annually for gastric cancer. All of our patients, except one who received D1 surgery and was therefore ineligible, underwent surgery that was at least D2. The rate of local relapse in the surgery-only group was 2.8% (15 of 530 patients), indicating that surgery alone was satisfactory in terms of local control. In all, 29% of patients underwent splenectomy, whereas 4% underwent pancreatectomy.

After a median follow-up of 2.9 years, the rate of overall survival was higher in the S-1 group than in the surgery-only group. This outcome is consistent with the results of a previous trials conducted in Japan.^{3,25} Our results are also consistent with those of a meta-analysis showing that the hazard ratio for death among patients who received S-1, as compared with those who did not, ranged from 0.70 to 0.82.¹⁻⁶ In addition, the effectiveness of postoperative adjuvant chemotherapy with S-1 for gastric cancer is consistent with the high response rates among patients with advanced gastric cancer.^{14,15} Adverse events of grade 3 or grade 4 occurred in less than 5% of patients in the S-1 group, except for anorexia (which occurred in 6% of patients), and compliance with S-1 treatment was good. We therefore believe that S-1 is useful as adjuvant chemotherapy after curative surgery in patients with gastric cancer.

Table 3. Site of First Relapse, According to Treatment Group.*

Site	S-1 (N = 529) no. of patients (%)	Surgery Only (N = 530) no. of patients (%)	Hazard Ratio for Relapse in the S1 Group (95% CI)	P Value
Total no. of relapses	133 (25.1)	188 (35.5)		
Local	7 (1.3)	15 (2.8)	0.42 (0.16–1.00)	0.05
Lymph nodes	27 (5.1)	46 (8.7)	0.54 (0.33–0.87)	0.01
Peritoneum	59 (11.2)	84 (15.8)	0.64 (0.46–0.89)	0.009
Hematogenous	54 (10.2)	60 (11.3)	0.84 (0.58–1.21)	0.35

* Some patients had a first relapse at more than one site.

Our results were obtained at a median follow-up of 2.9 years after randomization (median follow-up after surgery, 3.0 years). The survival rate 3 years after surgery was 80.5% in the S-1 group and 70.1% in the surgery-only group. These results were similar to those obtained when survival rates were measured from the date of randomization, with a hazard ratio for death in the S-1 group, as compared with the surgery-only group, of 0.68 ($P=0.002$). The results may change marginally at the 5-year follow-up. However, the number of events in the surgery-only group has already reached nearly 80% of that initially predicted for 5 years. At the first interim analysis, the predicted probability that overall survival in the S-1 group would be significantly better than that in the surgery-only group at final analysis was estimated to be 99.3%.²⁶

Although it has sometimes been suggested that there may be differences in certain aspects of gastric cancer in Japan and the West, there have been no significant differences identified between Japan and the United Kingdom with regard to possible genetic influences or between Japan and European countries in the distribution of important prognostic factors.²⁷⁻²⁹ Moreover, Italian investigators have reported that pancreas-preserving D2 dissection performed at centers with experience in this procedure can provide a survival benefit.³⁰ If adequate D2 dissection were performed, we believe that treatment outcomes in Western countries would be similar to those in Japan. We acknowledge that the results of our trial may not be valid in countries where D2 surgery is not considered the standard operation.




Figure 2. Hazard Ratios for Death and P Values for the Interaction of Treatment Group and Baseline Characteristic among Eligible Patients.

In the surgery-only group, the cancers in three patients could not be classified as differentiated or undifferentiated; one of these patients is still alive.

Supported by a grant from Taiho Pharmaceutical, Tokyo.

Drs. Sakuramoto, Sasako, Yamaguchi, Kinoshita, Fujii, Nashimoto, Nakajima, Imamura, Yamamura, and Kurita report receiving lecture fees from Taiho Pharmaceutical; and Dr. Ohashi, consulting and lecture fees from Taiho Pharmaceutical. No

other potential conflict of interest relevant to this article was reported.

We thank Professor J. Patrick Barron of the International Medical Communications Center of Tokyo Medical University for his review of an earlier version of this manuscript.

APPENDIX

Members of the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) group were as follows: **Steering Committee:** M. Sasako, T. Yamaguchi, T. Kinoshita, M. Fujii, A. Nashimoto, H. Furukawa; **Independent Data and Safety Monitoring Committee:** K. Yoshino, Y. Ohashi, Y. Maehara, A. Ohtsu; **Medical Advisor:** T. Nakajima; **Statistical Analyst:** Y. Ohashi; **Principal Investigators (all in Japan):** Sapporo Medical University Hospital — K. Yamaguchi; Shinnittetsu Muroran General Hospital — M. Takahashi, Y. Suzuki; Hokkaido University Hospital — S. Okushiba, S. Hirano, H. Manase, T. Shichinohe; Hirosaki University Hospital — H. Kawasaki; Iwate Medical University Hospital — M. Terashima, A. Takagane, H. Fujiwara; Iwate Prefectural Central Hospital — I. Mochizuki; National Hospital Organization Sendai Medical Center — T. Saito; Miyagi Cancer Center — T. Fujiya; Tohoku University Hospital — K. Shiiba, T. Mizoi, T. Kobayashi; Yamagata Prefectural Central Hospital — N. Fukushima; Yamamoto Kumiai General Hospital — K. Aoki; Fukushima Medical University Hospital, Surgery I — M. Gotoh; Fukushima Medical University Hospital, Surgery II — S. Takenoshita;

Tsuboi Hospital — N. Koyama, K. Nakayama, N. Sakurazawa; Saiseikai Niigata Daini Hospital — T. Aiba, Y. Sakai; Niigata Cancer Center Hospital — A. Nashimoto; Gunma University Hospital — E. Mochiki, R. Aihara; Gunma Prefectural Cancer Center — T. Fukuda, N. Kawano; Tsuchiura Kyodo General Hospital — S. Hiranuma; Tsukuba University Hospital — K. Ohta, N. Ohkohchi, S. Inagawa; Dokkyo Medical University Hospital — K. Sasaki; Tochigi Cancer Center — T. Inada; Saitama Cancer Center — Y. Tanaka; Dokkyo Medical University Koshigaya Hospital — S. Akao, M. Yamaguchi; Saitama Medical University Hospital — I. Koyama, R. Hirayama, W. Ichikawa; Chiba University Hospital — T. Suzuki, Y. Gunji, Y. Nabeya; National Cancer Center Hospital East — T. Kinoshita; Chiba Rousai Hospital — H. Nose, K. Kusano; Chiba Cancer Center — N. Takiguchi; International Medical Center of Japan — T. Shimizu; Showa University Toyosu Hospital — K. Kumagai; National Cancer Center Hospital — M. Sasako; Fraternity Memorial Hospital — S. Miyoshi; Tokyo Metropolitan Bokutoh Hospital — S. Inoue; Showa University Hospital — S. Suzuki, Y. Tajima; Tokyo Metropolitan Komagome Hospital — K. Arai, Y. Iwasaki; Mitsui Memorial Hospital — A. Umemura; Cancer Institute Hospital — T. Yamaguchi; Nihon University Itabashi Hospital — M. Fujii, T. Takayama; Tokyo Metropolitan Fuchu Hospital — J. Matsumoto; Showa General Hospital — M. Teruya; Keio University Hospital — T. Kubota, Y. Otani, Y. Saikawa; National Hospital Organization Tokyo Medical Center — K. Kubochi; St Luke's International Hospital — S. Ohigashi; Tokyo Medical and Dental University Hospital — T. Kawano; Kitasato University East Hospital — H. Shima, S. Sakuramoto; Yokohama City University Medical Center — T. Imada, C. Kunisaki; Yokohama Municipal Citizens' Hospital — M. Takahashi; Kanagawa Cancer Center — M. Sairenji, O. Kobayashi; Yokosuka Kyosai Hospital — H. Hosoi, K. Nagahori; Yokohama Rosai Hospital — M. Ozaki; Saiseikai Yokohamashi Nanbu Hospital — T. Suda, H. Ike; Shizuoka General Hospital — M. Takagi; Fujieda Municipal General Hospital — H. Yokoyama; Showa Inan General Hospital — K. Hayashi; Shinshu University Hospital — A. Sugiyama, N. Koide; Nagano Municipal Hospital — Y. Munakata; Gifu Municipal Hospital — H. Tanemura; Ogaki Municipal Hospital — Y. Kaneoka; Chukyo Hospital — M. Matsuda; Aichi Cancer Center Hospital — Y. Yamamura; National Hospital Organization Nagoya Medical Center — K. Kondo; Aichi Medical University Hospital — T. Nonami; Aichi Cancer Center Aichi Hospital — H. Kojima; Kainan Hospital — A. Harada; Fukui-ken Saiseikai Hospital — Y. Asada; Fukui Red Cross Hospital — H. Yamamoto, F. Tanaka; Toyama Prefectural Central Hospital — M. Kaji; Kyoto Second Red Cross Hospital — A. Takenaka; Kyoto First Red Cross Hospital — H. Kurioka; NTT West Osaka Hospital — M. Kinuta, H. Yano; Osaka City General Hospital — M. Higashino; National Hospital Organization Osaka National Hospital — T. Tsujinaka; Osaka Medical Center for Cancer and Cardiovascular Diseases — M. Hiratsuka, I. Miyashiro; Sakai City Hospital — H. Furukawa, H. Imamura; Kinki University Hospital — A. Tanaka, H. Shigeoka, H. Imamoto; Osaka Red Cross Hospital — T. Kitai, T. Inomoto; Kansai Medical University Takii Hospital — Y. Nakane, K. Nakai; Minoh City Hospital — S. Iijima; Kobe University Hospital — Y. Hamabe, H. Ikuta, T. Kamigaki; Hyogo Cancer Center — S. Fujiwara, Y. Kanbara; Kansai Rosai Hospital — S. Tamura; Hiroshima University Hospital — K. Yoshida; National Hospital Organization Kure Medical Center and Chugoku Cancer Center — M. Koseki; Hiroshima City Asa Hospital — W. Takiyama; Hiroshima Red Cross & Atomic-bomb Survivors Hospital — T. Ishida; Shimane Prefectural Central Hospital — N. Osaki; Tottori University Hospital — S. Tsujitani; Okayama Saiseikai General Hospital — N. Tsutsui; Yamaguchi University Hospital — S. Yoshino; Tokushima University Hospital — M. Nishi, N. Kurita; National Hospital Organization Shikoku Cancer Center — A. Kurita; Matsuyama Red Cross Hospital — T. Matsusaka, T. Nishizaki; National Hospital Organization National Kyushu Cancer Center — T. Okamura, M. Haraguchi, Y. Toh; National Hospital Organization Kyushu Medical Center — K. Ikejiri; Kitakyushu Municipal Medical Center — T. Iwashita; Fukuoka University Chikushi Hospital — K. Futami; Saiseikai Fukuoka General Hospital — T. Kusumoto; Kokura Memorial Hospital — M. Sugano, Y. Arima, A. Tanaka; Social Insurance Tagawa Hospital — T. Tanaka; Saga Prefectural Hospital Koseikan — T. Kusumoto, H. Orita; Sasebo City General Hospital — H. Ishikawa; National Hospital Organization Nagasaki Medical Center — K. Miyashita; Miyazaki Prefectural Miyazaki Hospital — K. Toyoda, T. Shimozone; Oita Prefectural Hospital — T. Kano, T. Ikeda; Saiseikai Kumamoto Hospital — N. Shigaki; Kumamoto Regional Medical Center — Y. Yagi; Japanese Red Cross Kumamoto Hospital — T. Hirata; and National Hospital Organization Kumamoto Medical Center — Y. Haga, H. Matsuzaki, M. Kai, N. Yoshida.

REFERENCES

- Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. *J Clin Oncol* 1993; 11:1441-7.
- Hermans J, Bonenkamp JJ. In reply. *J Clin Oncol* 1994;12:879-80.
- Nakajima T, Ohta K, Ohyama S, Hamajima N. Meta-analysis of adjuvant chemotherapy trials for gastric cancer at the Cancer Institute Hospital, Tokyo. In: Nakajima T, Yamaguchi T, eds. Multimodality therapy for gastric cancer. Tokyo: Springer-Verlag, 1999:27-31.
- Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. *Eur J Cancer* 1999;35:1059-64.
- Mari E, Floriani I, Tinassi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. *Ann Oncol* 2000;11:837-43.
- Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. *Tumori* 2002;88:21-7.
- Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-30.
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20.
- Macdonald JS, Smalley SR, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction: update of the results of Intergroup Study INT-0116 (SWOG9008). Presented at the 2004 Gastrointestinal Cancers Symposium, San Francisco, January 22-24, 2004. abstract.
- Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. *Ann Surg Oncol* 2002;9:278-86.
- Nakajima T. Gastric cancer treatment guidelines in Japan. *Gastric Cancer* 2002;5: 1-5.
- Shirasaka T, Shimamoto Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. *Anticancer Drugs* 1996;7:548-57.
- Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. *Oncology (Williston Park)* 1999;13: Suppl:17-21.
- Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. *Eur J Cancer* 1998;34:1715-20.
- Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel

- oral derivative of 5-fluorouracil, in advanced gastric cancer. *Oncology* 2000;58:191-7.
16. Kochi M, Fujii M, Kanamori N, et al. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. *Cancer Chemother Pharmacol* 2007;60:693-701.
17. Kinoshita T, Nashimoto A, Yamamura Y, et al. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. *Gastric Cancer* 2004;7:104-9.
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma — 2nd English edition. *Gastric Cancer* 1998;1:10-24.
19. Zelen M. The randomization and stratification of patients to clinical trials. *J Chronic Dis* 1974;27:365-75.
20. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. *Lancet* 1999;354:273-7.
21. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. *Stat Med* 1982;1:121-9.
22. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. *Biometrika* 1983;70:659-63.
23. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. *J Clin Oncol* 2003;21:2282-7.
24. Miyashiro I, Furukawa H, Sasako M, et al. No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer: randomized trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer. Presented at the 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, January 27-29, 2005. abstract.
25. Kinoshita T, Nakajima T, Ohashi Y. Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: results of a randomized trial by national surgical adjuvant study of gastric cancer. *Prog Proc Am Soc Clin Oncol* 2005;23:Suppl:313s. abstract.
26. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. *J R Stat Soc A* 1994;157:357-87.
27. McCulloch PG, Ochiai A, O'Dowd GM, Nash JR, Sasako M, Hirohashi S. Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan. *Cancer* 1995;75:920-5.
28. Bonenkamp JJ, van de Velde CJH, Kampschöer GHM, et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. *World J Surg* 1993;17:410-5.
29. Bollschweiler E, Boettcher K, Hoelscher AH, et al. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. *Br J Surg* 1992;79:156-60.
30. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. *Br J Cancer* 2004;90:1727-32.

Copyright © 2007 Massachusetts Medical Society.

POWERPOINT SLIDES OF JOURNAL FIGURES AND TABLES

At the *Journal's* Web site, subscribers can automatically create PowerPoint slides. In a figure or table in the full-text version of any article at www.nejm.org, click on Get PowerPoint Slide. A PowerPoint slide containing the image, with its title and reference citation, can then be downloaded and saved.

Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer

T. Nakajima¹, T. Kinoshita², A. Nashimoto³, M. Sairenji⁴, T. Yamaguchi¹, J. Sakamoto⁵, T. Fujiya⁶, T. Inada⁷, M. Sasako⁸ and Y. Ohashi⁹, on behalf of the National Surgical Adjuvant Study of Gastric Cancer Group

¹Department of Gastrointestinal Surgery, Cancer Institute Hospital, Tokyo, ²Department of Upper Abdominal Surgical Oncology, National Cancer Centre Hospital East, Chiba, ³Department of Surgery, Niigata Cancer Centre Hospital, Niigata, ⁴Department of Surgery, Kanagawa Cancer Centre, Kanagawa, ⁵Department of Surgery, Aichi Cancer Centre, Aichi Hospital, Aichi, ⁶Department of Surgery, Miyagi Cancer Centre, Miyagi, ⁷Department of Surgery, Tochigi Cancer Centre, Tochigi, ⁸Department of Surgical Oncology, National Cancer Centre Hospital, Tokyo, and ⁹Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo, Tokyo, Japan

Correspondence to: Dr T. Nakajima, Department of Gastrointestinal Surgery, Cancer Institute Hospital, 3-10-6, Ariake, Koto-ku, Tokyo 135-8550, Japan (e-mail: nakajima@jcr.or.jp)

Background: This prospective randomized study compared the survival of patients with tumour node metastasis (TNM) stage T2 N1–2 gastric cancer treated by gastrectomy alone or gastrectomy followed by uracil–tegafur.

Methods: Patients were randomly assigned to surgery alone or to surgery and postoperative uracil–tegafur 360 mg per m² per day orally for 16 months. The primary endpoint was overall survival. Relapse-free survival and site of recurrence were secondary endpoints.

Results: Of 190 registered patients, 95 were randomized to each group; two patients with early cancer were subsequently excluded from the chemotherapy group. The trial was terminated before the target number of patients was reached because accrual was slower than expected. Drug-related adverse effects were mild, with no treatment-related deaths. At a median follow-up of 6.2 years, overall and relapse-free survival rates were significantly higher in the chemotherapy group (hazard ratio for overall survival 0.48, $P = 0.017$; hazard ratio for relapse-free survival 0.44, $P = 0.005$), confirming the survival benefit shown in an interim analysis performed 2 years earlier.

Conclusion: Interim and final analyses revealed a significant survival benefit for postoperative adjuvant chemotherapy with uracil–tegafur in patients with serosa-negative, node-positive gastric cancer. Registration number: NCT00152243 (<http://www.clinicaltrials.gov>).

Presented to a meeting of the American Society of Clinical Oncology, Orlando, Florida, USA, May 2005

Paper accepted 28 September 2007

Published online 18 October 2007 in Wiley InterScience (www.bjs.co.uk). DOI: 10.1002/bjs.5996

Introduction

Although recent meta-analyses have suggested that adjuvant chemotherapy provides a significant survival benefit after curative gastrectomy in patients with locally advanced gastric cancer^{1–8}, few individual trials have demonstrated this. Trials of adjuvant chemotherapy have

suggested that future studies would require appropriate selection of the target population and intensive dosage regimens based on evidence⁹. After several multicentre clinical trials had produced negative results^{10–26}, the present authors designed a new dose escalation study with a simple regimen of uracil–tegafur in a well defined target population.

Most previous studies used uracil–tegafur in an adjuvant context in combination with other drugs. The daily dose was generally 300–400 mg (188–250 mg/m²), lower than

The Editors have satisfied themselves that all authors have contributed significantly to this publication

that recommended as monotherapy, to ensure safety²⁵. Studies with multiple drug regimens have generally shown negative or marginal survival benefits, although a trial in patients with moderately locally advanced gastric cancer of tumour node metastasis (TNM) stage T2 N1–2 demonstrated better survival after adjuvant chemotherapy with uracil–tegafur and mitomycin C than surgery alone²⁵.

In 1997, the National Surgical Adjuvant Study Group decided to perform large, simple clinical trials of uracil–tegafur monotherapy with intensive dosage regimens in breast, colorectal and gastric cancer. In accordance with the standard dose of uracil–tegafur for advanced gastric cancer²⁷ (response rate 27.5 per cent), 360 mg per m² per day was used for 5 days, followed by 2 days of rest, for 16 months. The total dose of uracil–tegafur with this regimen was almost identical to that used for conventional multiple drug regimens (210 mg/m² daily for 18 months). In the present study this regimen alone was used in a well defined subset of patients who had undergone curative gastrectomy.

Methods

Eligible patients with T2 N1–2 gastric cancer who had undergone curative gastrectomy and extended lymph node (D2) dissection (complete (R0) resection) were randomly assigned to control or chemotherapy groups within 6 weeks

Table 1 Characteristics of the 188 patients

	Chemotherapy (n = 93)	Control (n = 95)
Sex ratio (M:F)	70:23	73:22
Median age (years)	63	64
Depth of tumour invasion (pT2)		
Muscularis propria	49	46
Subserosa	44	49
Lymph node metastasis*		
n1	69	72
n2	24	23
Type of gastrectomy		
Total	34	26
Distal	59	67
Proximal	0	2
Lymph node dissection*		
D2	80	80
D3	7	8
D4	6	7

*Japanese Classification of Gastric Carcinoma²⁹.

of surgery. A dynamic allocation technique (modified minimization technique) was used for randomization at a central registration centre, with N stage (N1 or N2) and institution as adjustment variables. Random allocation was strictly controlled by an independent National Surgical Adjuvant Study Group Data Centre, and institutional data monitoring was carried out to avoid investigator-related bias.

Within 6 weeks of surgery, patients allocated to the chemotherapy group received an oral daily dose of




Fig. 1 CONSORT flow chart




Fig. 2 Overall survival in **a** all 188 eligible patients, **b** 141 patients with N1 cancer and **c** 47 patients with N2 cancer. **a** $P = 0.017$, **b** $P = 0.061$, **c** $P = 0.124$ (stratified log rank test)

uracil-tegafur of 360 mg/m² for 5 days every week for 16 months. Patients allocated to the control group were followed up with no adjuvant chemotherapy. Eligibility criteria included histologically proven adenocarcinoma of the stomach, curative gastrectomy with D2 or greater lymph node dissection, pathological T2 N1–2 gastric cancer, an Eastern Cooperative Oncology Group performance status of 0–2, age between 20 and 75 years, no previous chemotherapy and adequate organ function (leucocyte count over 4000 per mm³, platelet count above 100 000 per mm³, aspartate and alanine aminotransferase levels lower than twice the upper limit of normal (ULN) at the centre performing the test, total bilirubin concentration less than 1.5 times the ULN, blood urea nitrogen level less

than 1.5 times the ULN, and creatinine concentration less than 1.5 times the ULN). Written informed consent was obtained from all patients after approval of the Institutional Review Board at each participating centre.

Statistical analysis

The primary endpoint of the trial was overall survival. Secondary endpoints were relapse-free survival and site of relapse. Overall and relapse-free survival rates were calculated using the Kaplan–Meier method. P values were derived with the stratified log rank test according to N stage. Hazard ratios (HRs) were calculated by Cox regression analysis using N stage as a co-variate.

Table 2 Adverse events

	Chemotherapy (n = 92)*		Control (n = 94)*	
	Grade 3†	Grade 4†	Grade 3†	Grade 4†
All events	29 of 92 (32)	1 of 92 (1)	4 of 94 (4)	0 of 94 (0)
Neutropenia	11 of 83 (13)	0 of 83 (0)	0 of 78 (0)	0 of 78 (0)
Anaemia	1 of 91 (1)	0 of 91 (0)	0 of 92 (0)	0 of 92 (0)
Raised AST level	1 of 91 (1)	0 of 91 (0)	2 of 92 (2)	0 of 92 (0)
Raised ALT level	2 of 91 (2)	0 of 91 (0)	2 of 92 (2)	0 of 92 (0)
Hyperbilirubinemia‡	8 of 89 (9)	0 of 89 (0)	2 of 90 (2)	0 of 90 (0)
Nausea/vomiting	1 of 92 (1)	0 of 92 (0)	0 of 94 (0)	0 of 94 (0)
Diarrhoea	1 of 92 (1)	1 of 92 (1)	0 of 94 (0)	0 of 94 (0)
Infection	1 of 92 (1)	0 of 92 (0)	0 of 94 (0)	0 of 94 (0)
Anorexia	6 of 92 (7)	0 of 92 (0)	0 of 94 (0)	0 of 94 (0)
Rash	1 of 92 (1)	0 of 92 (0)	0 of 94 (0)	0 of 94 (0)

Values in parentheses are percentages. *One patient excluded from chemotherapy group for refusal of drug administration, and one from control group at patient's request. †Japan Clinical Oncology Group criteria²⁸. ‡More than twice the upper limit of normal. AST, aspartate aminotransferase; ALT, alanine aminotransferase.

The 5-year overall survival rate of this patient subset (T2 N1–2) was 70 per cent in a previous study²⁵, and a 33 per cent reduction in the HR was expected (corresponding to a 5-year overall survival rate of 78.8 per cent). The necessary sample size was 244 patients per group, assuming a 3-year accrual period and 5-year follow-up, with a statistical power of 80 per cent to achieve a one-sided significance level of 0.050. The accrual goal was 500 patients. All analyses were based on intention-to-treat groups.

An Independent Data Monitoring Committee (IDMC) monitored the trial. Two interim analyses were originally planned, 1 and 3 years after all patients had been enrolled. Significance levels were set at 0.005 and 0.020 (one-sided) respectively. After closing the registration, the IDMC decided to undertake a single interim analysis at 2 years, owing to a lower rate of accrual than anticipated. When this interim analysis revealed a difference in survival rates between the two groups, the IDMC did not disclose this finding to investigators. Second interim and final analyses were then undertaken as originally planned at 3 and 5 years. Adverse events were evaluated using the toxicity grading criteria of the Japan Clinical Oncology Group²⁸.

Multivariable analysis was carried out with a Cox proportional hazards model to identify independent prognostic factors using treatment group, sex, age group, depth of invasion and extent of lymph node metastasis as explanatory variables.

Results

As accrual was slower than expected, recruitment of patients was terminated midway through the trial before


the target number of patients was reached. Between June 1997 and March 2001, 190 patients were enrolled in the study, 95 randomized to the chemotherapy group and 95 to the control group. Two patients were ineligible after randomization and were excluded from the analysis because the final pathological report revealed early gastric cancer. Thus, 188 patients, 93 in the chemotherapy and 95 in the control group, were included in the intention-to-treat analysis (Fig. 1).

Clinical characteristics of the 188 patients are shown in Table 1. All major prognostic factors were similar in the two groups.

Of patients in the chemotherapy group with no recurrence, 80 per cent (73 of 91) received all scheduled doses of uracil–tegafur during the first 3 months, and 51 per cent (44 of 86) did so for 16 months. Two patients were withdrawn from treatment as a result of recurrence during the first 3 months, and seven for recurrence by 16 months.

Adverse events during follow-up are shown in Table 2. The main events in the chemotherapy group were bone marrow suppression (grade 3 neutropenia, 13 per cent), liver dysfunction (grade 3 hyperbilirubinaemia, 9 per cent) and gastrointestinal dysfunction (grade 3 anorexia, 7 per cent). Grade 4 diarrhoea occurred in one patient in the chemotherapy group.

At the 2-year interim analysis conducted in December 2003, both overall and relapse-free survival rates were significantly better in the chemotherapy group. The second interim analysis was conducted in November 2004 after a median follow-up of 3.8 years (3 years after registration



No. at risk							
Chemotherapy	93	86	82	79	76	66	33
Control	95	78	69	63	63	57	24

Fig. 3 Relapse-free survival in patients in the chemotherapy group compared with that in the control group. $P = 0.005$ (log rank test)

Table 3 First site of relapse

	Chemotherapy (n = 93)	Control (n = 95)	P*
Peritoneal	4	3	0.680
Local	0	4	0.050
Haematogenous	9	14	0.290
Distant lymph nodes	2	11	0.010
Total no. of relapses	13	28	

Some patients had more than one type of recurrence. * χ^2 test.

was closed). Survival rates remained significantly better in the chemotherapy group (HR 0.46, 13 per cent difference in survival at 4 years).

These survival benefits were confirmed by the final analysis, performed after a median follow-up of 6.2 years after surgery (5 years after registration was closed). The 5-year overall survival rate was 86 per cent in the chemotherapy group and 73 per cent in the control group ($P = 0.017$) (Fig. 2a). The HR for overall survival in the chemotherapy group relative to the control group was 0.48 (95 per cent confidence interval (c.i.) 0.26 to 0.89). Figs 2b and 2c show the results of a planned subset analysis of overall survival according to N1 (HR 0.52 (95 per cent c.i. 0.26 to 1.05); $P = 0.061$) and N2 (HR 0.40 (95 per cent c.i. 0.12 to 1.34); $P = 0.124$) status. The results of a similar analysis of 5-year relapse-free survival in chemotherapy and control groups are shown in Fig. 3 (85 versus 68 per cent respectively; HR 0.44 (95 per cent c.i. 0.25 to 0.79); $P = 0.005$).

Multivariable analysis showed that treatment group ($P = 0.021$) and sex ($P = 0.032$) were significant independent prognostic factors, whereas the other three explanatory variables were not (age group, $P = 0.918$; depth of cancer invasion, $P = 0.539$; extent of lymph node metastasis, $P = 0.996$).

All causes of death included 13 recurrences in the chemotherapy group, 28 in the control group, two deaths from other cancers in the chemotherapy group, and one death unrelated to disease (traffic accident) and one for unknown reasons in the control group.

Table 3 shows the first sites of relapse in the two groups. The most common type of relapse was haematogenous metastasis to the liver. Patients in the chemotherapy group had a lower incidence of nodal metastatic recurrence.

Discussion

Both the second interim analysis after a median follow-up of 3.8 years and the final analysis after a median of 6.2 years showed a significant survival benefit for patients with T2

N1–2 gastric cancer following curative D2 gastrectomy and adjuvant chemotherapy with uracil–tegafur. Previous studies of adjuvant chemotherapy have not shown such a significant benefit^{30–32}.

Kato and colleagues³³ first reported the survival benefit of adjuvant uracil–tegafur alone in non-small cell lung cancer after curative surgery. Uracil–tegafur is widely used in Japan, but not in other countries. This is the first report to document a significant survival benefit for adjuvant uracil–tegafur in patients with gastric cancer.

The unexpectedly large difference in survival between the groups is a cause for concern. Such a significant finding was unexpected because the number of patients was much smaller than planned. Slow accrual might have been due partly to a lack of enthusiasm among investigators for the use of uracil–tegafur, on the basis of earlier trials. Some eligible patients might have been enrolled in other concurrent trials with similar eligibility criteria. Although some institutional selection bias may have been present, this was not reflected in the allocation of registered patients. The interim analysis unexpectedly revealed a HR of 0.46, corresponding to a 13 per cent difference in 4-year overall survival rate, at a median follow-up of 3.8 years, reaching the predefined significance level. The survival difference continued for more than 5 years after surgery and was confirmed at the final analysis, after a median follow-up of 6.2 years.

The large reductions in HR for overall and relapse-free survival may be attributable to several factors. One is the difference in the clinical stage of disease between the patients in this and earlier studies conducted by this group^{25,26}. Patients in the present study had T2 N1–2 gastric cancer, whereas the authors' previous study included patients with T1 and T2 N1–2 disease. The exclusion of T1 cancer from the present study resulted in poorer 5-year overall survival in the control group than in the earlier trial, but almost no change in overall survival in the chemotherapy group, resulting in a significant survival difference. The difference in survival may therefore have been attributable to better patient selection, a higher dosage of uracil–tegafur than used in previous regimens²⁵ and a long duration of treatment.

A second concern was whether the survival difference actually resulted from the chemotherapy. Small numbers of patients per centre might theoretically bias the allocation of patients to treatment, but there was no evidence of this. Treatment allocation was strictly controlled by an independent data centre, minimizing the possibility of bias related to centre or investigator. The clinical characteristics of both chemotherapy and control groups were similar, and only two patients (1.1 per cent) were excluded from

analysis because of protocol violations (early cancer). The rate of compliance with treatment was 80 per cent during the first 3 months of chemotherapy and 51 per cent at the end of the study, despite the long treatment period. Lower compliance at the end of the study was due to adverse events, patient refusal or loss to follow-up. Compliance rates were consistent with those of other recent trials^{33–37}.

The cause of death was established in most patients. The incidence of distant lymph node relapse was significantly lower in the chemotherapy group, suggesting that after D2 dissection adjuvant chemotherapy might have inhibited the growth of minimal residual tumour in distant nodes. On subset analysis according to N1 and N2 status, the survivals of patients in the chemotherapy groups were almost identical, and the larger difference, though not statistically significant, in survival rate in patients with N2 disease might have resulted from a higher rate of residual cancer in distant nodes after D2 surgery than in those with N1 disease. No differences were observed in other types of relapse, such as liver or peritoneal metastasis. Multivariable analysis showed that treatment group and sex were significant independent prognostic factors, providing further evidence that the survival benefit was derived from adjuvant chemotherapy.

Although not widely used in Western countries until recently, adjuvant uracil–tegafur treatment appears to be effective in other cancers^{34–36}. The survival benefit achieved with oral uracil–tegafur plus leucovorin is similar to that with intravenous 5-fluorouracil and leucovorin, but with less toxicity, in colorectal cancer. Adjuvant chemotherapy with uracil–tegafur alone is effective in patients with non-small cell lung³³ and rectal³⁸ cancer. Apart from direct cytotoxic activity, low-dose chemotherapy with uracil–tegafur has been shown experimentally to have antiangiogenic effects on endothelial cells³⁹. This could also influence survival.

In the present trial, the main side-effect associated with uracil–tegafur alone was moderate myelosuppression. Uracil–tegafur alone is associated with milder side-effects than when combined with leucovorin^{35,36}. The advantages of survival benefit, mild toxicity and ease of administration on an outpatient basis make this an attractive approach. It was on this basis that a further large-scale clinical trial was recently undertaken in Japan using adjuvant S-1, a successor to uracil–tegafur that is anticipated to be more effective⁴⁰.

Patient selection is important in the context of adjuvant chemotherapy trials. It seems unreasonable to assume that a given regimen of adjuvant chemotherapy will be effective for all stages of disease. Conversely, selected groups of patients might benefit in terms of survival. Similarly, the

quality of surgery may also be important. D2 gastrectomy for patients in the present trial carried only a small risk of stage misclassification.

Whether the present results can be extrapolated to other countries is important. Provided that D2 gastrectomy can be performed with a high level of reliability and low perioperative mortality, these results should be reproducible, because the outcomes of adjuvant chemotherapy appear to depend largely on the amount of residual tumour and the quality of surgery⁴¹. Macdonald and colleagues³⁷ in the USA reported encouraging results for adjuvant chemoradiotherapy in patients who had undergone curative gastrectomy. Their results may be representative as well as reproducible in that country, where D2 lymph node dissection is not performed routinely. Inadequate surgery might have resulted in large amounts of residual tumour in that trial. Adjuvant chemoradiotherapy may have suppressed locoregional relapse, thereby compensating for inadequate lymph node dissection. Although there is no evidence to support the superiority of D2 over D1 (limited lymph node dissection) or D0 (local) resection⁴², many Japanese studies, as well as some reports from high-volume centres in Western countries, suggest that extended lymphadenectomy enhances postoperative survival^{43,44}. The regimen for adjuvant therapy with uracil–tegafur might produce different outcomes under different surgical resection standards.

Acknowledgements

The authors are indebted to Professor Derek Alderson, Department of Surgery, University of Birmingham, and Professor J. Patrick Barron, International Medical Communications Centre, Tokyo Medical University, for assistance with this manuscript. This trial was supported by the Japan Health Sciences Foundation and by Taiho Pharmaceutical Company, Tokyo, Japan.

Members of the National Surgical Adjuvant Study of Gastric Cancer were as follows. Trial Chair: T. Nakajima (Cancer Institute Hospital, Tokyo). Statistical Analyst: Y. Ohashi (University of Tokyo, Tokyo). Evaluation Committee: H. Nakazato (Yokoyama Gastrointestinal Hospital, Nagoya). Independent Data Monitoring Committee: N. Saijo (National Cancer Centre Hospital East, Chiba), Y. Ariyoshi (Marumo Hospital, Aichi), S. Ebihara (National Cancer Centre Hospital East, Chiba), H. Origasa (Toyama University, Toyama), M. Fukuoka (Kinki University, Osaka), T. Mitsuishi (Mitsuishi Law and Patent Office, Tokyo), T. Tsuruo (University of Tokyo, Tokyo). Participating Institutions and Principal Investigators: National

Hospital Organization Sendai Medical Centre, Miyagi (Y. Kunii, T. Saito); Miyagi Cancer Centre, Miyagi (T. Fujiya); Yamagata Prefectural Central Hospital, Yamagata (N. Fukushima); Ibaraki Prefectural Central Hospital, Ibaraki (N. Okazaki, Y. Miyata, M. Ohkuwa, H. Ohkura); Tochigi Cancer Centre, Tochigi (T. Inada); Gunma Prefectural Cancer Centre, Gunma (T. Fukuda, N. Haga); Saitama Cancer Centre, Saitama (Y. Suda, K. Uchida, Y. Kawashima); National Cancer Centre Hospital East, Chiba (T. Kinoshita); Chiba University Hospital, Chiba (T. Suzuki, Y. Gunji, Y. Nabeya); Cancer Institute Hospital, Tokyo (T. Takahashi, K. Ohta, T. Yamaguchi); Keio University Hospital, Tokyo (T. Kubota, Y. Otani, Y. Saikawa); National Cancer Centre Hospital, Tokyo (M. Sasako); Tokyo Metropolitan Komagome Hospital, Tokyo (M. Kitamura, K. Arai); Kanto Medical Centre, Nippon Telegraph and Telephone East Corporation, Tokyo (T. Konishi); Nihon University Itabashi Hospital, Tokyo (M. Fujii, T. Takayama); Kanagawa Cancer Centre, Kanagawa (M. Sairenji, O. Kobayashi); Niigata Cancer Centre Hospital, Niigata (J. Sasaki, A. Nashimoto); Kanazawa University Hospital, Kanazawa (S. Fushida); Aichi Cancer Centre Hospital, Aichi (Y. Yamamura); National Hospital Organization Nagoya Medical Centre, Aichi (K. Kondo, M. Kataoka); Aichi Cancer Centre Aichi Hospital, Aichi (J. Sakamoto, H. Kojima); Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka (H. Furukawa, M. Hiratsuka, I. Miyashiro); National Hospital Organization Osaka National Hospital, Osaka (T. Tsujinaka); Sakai Municipal Hospital, Osaka (M. Tatsuta); Hyogo Cancer Centre, Hyogo (S. Nakaya, K. Kawaguchi, Y. Kanbara); National Hospital Organization Kure Medical Centre, Hiroshima (T. Hashimoto, M. Koseki); Yamaguchi Grand Medical Centre, Yamaguchi (Y. Kuroda); Kagawa University Hospital, Kagawa (H. Usuki); National Hospital Organization Shikoku Cancer Centre, Ehime (A. Kurita); National Hospital Organization Kyushu Cancer Centre, Fukuoka (T. Saito, S. Kohnoe, T. Okamura); Kagoshima University Hospital, Kagoshima (T. Aiko).

References

- Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M *et al.* Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. *J Clin Oncol* 1993; **11**: 1441–1447.
- Hermans J, Bonenkamp JJ. In reply to the editor. *J Clin Oncol* 1994; **12**: 879–880.
- Nakajima T, Ohta K, Ishihara S, Ohyama S, Nishi M, Hamashima N. Evaluation of adjuvant chemotherapy in gastric cancer with meta-analysis. *Gan To Kagaku Ryobo* 1994; **21**: 1800–1805.
- Pignon J, Decreux M, Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. *J Clin Oncol* 1994; **12**: 877–878.
- Earle C, Maroun J. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. *Eur J Cancer* 1999; **35**: 1059–1064.
- Mari E, Floriani I, Tinassi A, Buda A, Belfiglio M, Valentini M *et al.* Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). *Ann Oncol* 2000; **11**: 837–843.
- Janunger K, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in gastric cancer. *Acta Oncol* 2001; **40**: 309–326.
- Panzini I, Gianni L, Fattori P, Tassinari D, Imola M, Fabbri P *et al.* Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. *Tumori* 2002; **88**: 21–27.
- Nakajima T. Success of adjuvant chemotherapy trials for gastric cancer. In *Multimodality Therapy for Gastric Cancer*, Nakajima T, Yamaguchi T (eds). Springer: Tokyo, 1999; 3–6.
- Nakajima T, Fukami A, Ohashi I, Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. *Int J Clin Pharmacol* 1978; **16**: 209–216.
- Nakajima T, Fukami A, Takagi K, Kajitani T. Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. *Jpn J Clin Oncol* 1980; **10**: 187–194.
- Huguier PH, Destroes JP, Baschet C, Le Henand F, Bernard PF. Gastric carcinoma treated by chemotherapy after resection: a controlled study. *Am J Surg* 1980; **139**: 197–199.
- Blake JR, Hardcastle JD, Wilson RG. Gastric cancer: a controlled trial of adjuvant chemotherapy following gastrectomy. *Clin Oncol* 1981; **7**: 13–21.
- Alcobendas F, Milla A, Estape J, Curto J, Pera C. Mitomycin C as adjuvant in resected gastric cancer. *Ann Surg* 1983; **198**: 13–17.
- Fielding JW, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A *et al.* An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. *World J Surg* 1983; **7**: 390–399.
- Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T. Comparison of 5-fluorouracil with fluorouracil in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. *J Clin Oncol* 1984; **2**: 1366–1371.
- Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer:

- interim report. British Stomach Cancer Group. *Br J Cancer* 1989; **60**: 739–744.
- 18 Allum WH, Hallissey MT, Kelley KA. Adjuvant chemotherapy in operable gastric cancer: 5 year follow-up of first British Stomach Cancer Group trial. *Lancet* 1989; **18**: 571–574.
 - 19 Krook JE, O'Connell MJ, Wieand HS, Beard RW Jr, Leigh JE, Kugler JW *et al.* A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. *Cancer* 1991; **67**: 2454–2458.
 - 20 Nakajima T, Okabayashi K, Nakazato H, Imanaga T, Ohta K, Kinoshita T *et al.* Effect of MFC-based adjuvant chemo-therapy in gastric cancer with curative surgery. *Jpn J Soc Cancer Ther* 1994; **29**: 654–662.
 - 21 Lise M, Nitti D, Marchet A, Sahnoud T, Buyse M, Duez N *et al.* Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. *J Clin Oncol* 1995; **13**: 2757–2763.
 - 22 Macdonald J, Fleming T, Peterson R, Berenberg J, McClure S, Chapman R *et al.* Adjuvant chemotherapy with 5-FU, Adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. *Ann Surg Oncol* 1995; **2**: 488–494.
 - 23 Crookes P, Leichman C, Leichman L, Tan M, Laine L, Stain S *et al.* Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. *J Clin Oncol* 1997; **79**: 1767–1775.
 - 24 Rosen H, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P *et al.* Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. *J Clin Oncol* 1998; **16**: 2733–2738.
 - 25 Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K *et al.* Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Gastric Cancer Surgical Study Group. *Lancet* 1999; **354**: 273–277.
 - 26 Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y *et al.* Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. *J Clin Oncol* 2003; **21**: 2282–2287.
 - 27 Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. *Cancer Chemother Pharmacol* 1988; **22**: 333–338.
 - 28 Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K *et al.* Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. *Jpn J Clin Oncol* 1993; **23**: 250–257.
 - 29 Japanese Research Society for Gastric Cancer. *Japanese Classification of Gastric Carcinoma*. Kanehara: Tokyo, 1995.
 - 30 Fielding JW. The value of a multidisciplinary approach in the management of gastric cancer. *Recent Results Cancer Res* 1988; **110**: 57–64.
 - 31 Sano T, Sasako M, Katai H, Maruyama K. Randomized controlled trials on adjuvant therapy for gastric cancer: Japanese experience. In *Multimodality Therapy for Gastric Cancer*, Nakajima T, Yamaguchi T (eds). Springer: Tokyo, 1999; 7–16.
 - 32 Douglass HJ, Nava H, Smith J. Multimodality therapy for completely resected (R0) gastric cancer (excluding Japanese trials). In *Multimodality Therapy for Gastric Cancer*, Nakajima T, Yamaguchi T (eds). Springer: Tokyo, 1999; 17–26.
 - 33 Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H *et al.* A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. *N Engl J Med* 2004; **350**: 1713–1721.
 - 34 Feliu J, Gonzalez Baron M, Espinosa E, Garcia Giron C, de la Gandara I, Espinosa J *et al.* Uracil and tegafur modulated with leucovorin. An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. *Cancer* 1997; **79**: 1884–1889.
 - 35 Carmichael J, Popiela T, Radstone D, Falks K, Borner M, Oza A *et al.* Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2002; **20**: 3617–3627.
 - 36 Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P *et al.* Multicenter phase III study of uracil–tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2002; **20**: 3605–3616.
 - 37 Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN *et al.* Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; **345**: 725–730.
 - 38 Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S, for the National Surgical Adjuvant Study of Colorectal Cancer. Adjuvant chemotherapy with uracil–tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. *Jpn J Clin Oncol* 2006; **36**: 237–244.
 - 39 Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. *Nat Rev Cancer* 2004; **4**: 423–436.
 - 40 Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. *Oncology* 2000; **58**: 191–197.
 - 41 Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T, Southwest Oncology Group and the Gastric Intergroup. Surgical treatment variation in a prospective, randomized

- trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. *Ann Surg Oncol* 2002; **9**: 278–286.
- 42 Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I *et al.* Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. *N Engl J Med* 1999; **340**: 908–914.
- 43 Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. *J Clin Oncol* 2005; **23**: 7114–7124.
- 44 Peeters KC, Hundahl SA, Kranenbarg EK, Hartgrink H, van de Velde CJ. Low maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1–D2 trial. *World J Surg* 2005; **12**: 1576–1584.

If you wish to comment on this, or any other article published in the *BJS*, please visit the on-line correspondence section of the website (www.bjs.co.uk). Electronic communications will be reviewed by the Correspondence Editor and a selection will appear in the correspondence section of the Journal. Time taken to produce a thoughtful and well written letter will improve the chances of publication in the Journal.

Phase II Study of 2-Week TS1 Administration followed by 1-Week Rest for Gastric Cancer

Hiroshi Imamura¹, Hiroshi Furukawa¹, Tomono Kishimoto¹, Siro Nakane²
Kentaro Inoue³, Yasuo Tsukahara⁴, Motohiro Imamoto⁵, Keiji Yamazaki⁶, Shinji Okano⁷
Suguru Morimoto⁸, Seichi Sugihara⁹, Toshio Shimokawa¹⁰

¹Department of Surgery, Sakai Municipal Hospital, Osaka; ²Department of Surgery, Saiseikai Nakatsu Hospital Osaka; ³Department of 2nd Surgery, Kansai Medical University, Osaka; ⁴Department of Surgery Toyonaka Municipal Hospital, Osaka; ⁵Department of Surgery, Kinki University, Osaka; ⁶Department of Surgery, Saiseikai Senri Hospital, Osaka; ⁷Department of Surgery Matsushita Memorial Hospital, Osaka; ⁸Department of Surgery, Yao Municipal Hospital, Osaka; ⁹Department of Surgery, Hoshigaoka Welfare Annuity Hospital, Osaka; and ¹⁰Department of Ecosocial System, Yamanashi University, Yamanashi, Japan

Corresponding Author: Dr. Hiroshi Imamura, 1-1-1, Minamiyasuicho, Sakai 590-0064 Japan
Tel: +81 72 221 1700, Fax: +81 72 225 3303, E-mail: imamura-h@city.sakai.osaka.jp

AUTHOR PLEASE INDICATE WHICH AUTHOR BELONGS TO THE HIGHLIGHTED DEPARTMENT

ABSTRACT

Background/Aims: TS-1 monotherapy with 4-week administration followed by 2-week rest is used as the community standard treatment for metastatic gastric cancer in Japan. However, according to a post-marketing survey, the percentage of patients who received three or more courses was only 44.6%; for the reasons of discontinuation due to exacerbation of symptoms or adverse reactions during the first or second course. Therefore, we conducted the phase II study of 2-weeks administration with TS-1 followed by a 1-week rest against metastatic gastric cancer, aiming for mitigation of adverse reactions without reduction of antitumor effect.

Methodology: Thirty-five patients were enrolled between 2001 and 2003 at nine institutes in Japan. One cycle of TS-1 treatment whose dosage was 80mg/m²/day consisted of administration for 2 weeks followed by a 1-week rest. The primary endpoint was

overall response rate and the secondary endpoints were safety and feasibility.

Results: There were 6 PRs, 13 NCs, 11 PDs, and 5 patients were not evaluable (NE), yielding a response rate of 17%. The median survival time of all patients was 290 days. Severe adverse Grade 3 or 4 reactions were observed in 8 (23%) patients. The rate of patients who received six or more courses was 43%. The cumulative rate of the relative total administration days was 93%.

Conclusions: We concluded that the schedule of TS-1 administration for 2 weeks followed by a 1-week rest might not be superior to the conventional schedule (4 weeks on and 2 weeks off) with regard to the antitumor effect, adverse reactions and prolonged medication, although it was acceptable from the point of survival view.

KEY WORDS:

TS-1; Gastric cancer; 2 weeks followed by a 1-week rest

ABBREVIATIONS:

Eastern Clinical Oncology Group (ECOG); Not Evaluable (NE); Computed Tomography (CT); Body Surface Area (BSA); No Change (NC); Progressive Disease (PD)

INTRODUCTION

5-FU remains the key drug of chemotherapeutic option for metastatic gastric cancer since it was first synthesized in 1957 (1). Among a number of regimens of 5-FU devised from the pharmacokinetic studies, continuous intravenous infusion of 5-FU for 4 weeks or more, which was reported to yield higher response rates than a bolus intravenous injection (2), has been usually used for the patients with metastatic gastric cancer. However, gastrointestinal mucosal injury was identified as dose-limiting toxicity of this regimen (3). This regimen necessarily immobilizes the patients for long periods in addition to complications due to indwelling catheters.

TS-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) (4), which is composed of a mixture of tegafur (FT, a prodrug of 5-FU), Gimeracil (CDHP, a biochemical modulator which inhibits the biodegradation of 5-FU) (5), and Oteracil potassium (Oxo, added to

reduce the gastrointestinal toxicity of 5-FU) (6), was developed as an oral anticancer agent in Japan in order to improve these disadvantages of 5-FU with continuous intravenous infusion. TS-1 showed the highest response rate among many oral anticancer agents against advanced carcinomas in phase II studies (7). The response rate against metastatic gastric cancer was 43.5%, which is the highest response rate in a single anticancer agent for gastric cancer (8). Therefore, TS-1 is one of the most frequently used anticancer agent as the community standard treatment for metastatic gastric cancer in Japan. However in premarketing clinical trials (8,9) and a postmarketing survey of 3294 patients (10), in which TS-1 was orally administered at the usual dose level (80mg/m²) for 4 weeks followed by a 2-week rest (conventional schedule) for metastatic gastric cancer, the incidence of adverse reactions was 83.2% and 74.1%, respectively, and especially the latter response rate was only

27%. The percentage of patients who received three or more courses was only 29.5%, the reasons why the discontinuation during the first or second course were mainly due to adverse reactions according to a post-marketing survey. The median time to the occurrence of the worst adverse reactions after TS-1 administration was 22 days for hematological toxicities and 15 days for diarrhea and stomatitis. Accordingly we conducted a phase II study of the new schedule of TS-1 therapy consisting of 2-week administration followed by 1-week rest (new schedule) for metastatic gastric cancer aiming at adverse reaction mitigation and prolonged medication without decreasing efficacy.

METHODOLOGY

Study Design

We conducted a multicenter phase II study that was approved by the institutional review boards of all participating hospitals and conducted in observance of the Declaration of Helsinki as well as good clinical practice guidelines. All patients provided written informed consent prior to enrollment in this study.

Patients

Thirty-five patients, enrolled between September 2001 and April 2003 at nine institutes in Japan, were required to satisfy the following eligibility criteria; 1) histologically proven gastric cancer; 2) metastatic or unresectable locally disease with one or more bidimensionally measurable target lesion documented radiographically; 3) age between 20 and 75 years; 4) Eastern Clinical Oncology Group (ECOG) scale performance status of 0, 1 or 2; 5) no prior chemotherapy or completion of adjuvant chemotherapy at least 4 weeks

before entry; 6) adequate function of the bone marrow (white blood cell count $\geq 4,000$ and $< 12,000$ / μL platelet count $\geq 100 \times 10^3$ / μL , hemoglobin ≥ 8.0 g/dL), liver (serum bilirubin ≤ 1.5 mg/dL, AST/ALT level 3 x upper limit of normal (N), alkaline phosphatase level $\leq 2 \times \text{N}$) and kidneys (serum creatinine $\leq \text{N}$); 7) normal cardiac function; 8) possibility of oral intake; no other severe medical conditions possibility of oral intake; 9) provision of give written informed consent. Exclusion criteria were as follows; 1) other active malignancy; 2) a high risk of poor outcome for concomitant nonmalignant disease (cardiac, pulmonary, renal, or hepatic disease, active uncontrolled infection, and chronic enteropathy); 3) the presence of CNS metastases 4) uncontrollable pleural effusion or ascites; 5) active gastrointestinal bleeding; 6) lactating women or those of childbearing potential. The eligibility of patients was checked once more via facsimile by the central data center (Osaka).

Treatment

Before study entry, all eligible patients were required to provide a medical history and to undergo a physical examination that included assessment of weight, height, and ECOG performance status. As clinical assessment of tumor size, assay of the tumor markers CEA and CA19-9, and enhanced computed tomographic (CT) scan were also performed. After confirmation of eligibility by the central data center (Osaka), TS-1 was administered using the following method. The dosage of TS-1, which was administered orally after meals, was selected as follows: in a patient with body surface area (BSA) $< 1.25 \text{ m}^2$, 40mg twice a day (80mg/day); BSA $\geq 1.25 \text{ m}^2$ but $< 1.5 \text{ m}^2$, 50mg twice a day (100mg/day); and BSA $\geq 1.5 \text{ m}^2$, 60mg twice a day (120mg/day). One cycle of TS-1 treatment in this study consisted of administration for 2 weeks followed by a 1-week rest. In patients with evidence of a grade 3 or higher toxicity, administration of TS-1 was discontinued until recovery from these adverse reactions and the dosage of restart after recovery from adverse reactions was planned to be reduced by one level (20mg/day). Treatment was suspended if the rest period was extended to over 4 weeks for adverse reactions. If a patient administered 80mg/day experienced the above toxicities, then no further treatment with more reduced dosage of TS-1 was continued.

Assessment of Response

The primary endpoint was response rate [ratio of patients attaining response (complete response - CR + partial response - PR)]. The assessment of tumor response was performed at least every 6 weeks. An independent external review committee consisting of radiologists, medical oncologists and surgeons assessed retrospectively tumor response. The antitumor effects were evaluated according to the Japanese Research Society for Gastric Cancer criteria, which was established by the WHO. This criteria was as follows: CR, eradication of all cancers and maintenance of the condition for 4 weeks or more; PR, 50% reduction in size of lesions and maintenance of the condition

TABLE 1 Patient Characteristics

Patients		35
Median age, years (range)		64 (37-75)
Gender	Male	27
	Female	8
Performance status (ECOG scale)	0	13
	1	20
	2	2
Initial dose (mg/day)	80	5
	100	11
	120	19
Extent of disease	Locoregional	1
	Primary and metastatic	7
	Metastatic only	28
Evaluable sites	Primary	8
	Lymph nodes	16
	Liver	12
	Lung	3
	Peritoneum	5
	Skin	1
	Adrenal gland	1
Histopathological type	Intestinal	19
	Diffuse	16
Prior chemotherapy	Adjuvant chemotherapy	2
	No chemotherapy	33

for 4 weeks or more; no change (NC), less than 50% reduction in size of lesions or enlargement of lesions within 25% and maintenance of the condition for 4 weeks or more; progressive disease (PD), 25% or more enlargement of lesions or appearance of new lesions. Primary gastric lesions were evaluated by improvement of gastrographic and/or endoscopic findings.

Assessment of Feasibility

All eligible patients who had received definitive treatment were considered assessable for feasibility and toxicity. Feasibility was evaluated by the percentage of patients in this study who received six or more courses, which was equivalent to three or more courses of administration for 4 weeks followed by a 2-week rest, and by the percentage of patients who discontinued within 4th course for the reason of adverse reactions. The cumulative rate of relative total administration days was calculated by the rate between the actual total administration days and planned total administration days of TS-1. All adverse reactions experienced during the study were evaluated according to the National Cancer Institute Common Toxicity Criteria (Version 2.0) by questioning and clinical examination at least every 3 weeks during study.

Statistical Methods

The primary endpoint of this study was ORR. The number of patients to be enrolled in this study was calculated at 27, which was required for dismissing the assumption that the 95% confidence interval (CI) would be $\pm 18\%$, assuming an expected response rate of 33%. Finally, we set it at 31 patients in consideration of 15% disqualified patients. Survival was estimated by the Kaplan-Meier method.

RESULTS

Patient Characteristics

Thirty-five patients were enrolled in this study between September 2001 and April 2003. The patient characteristics are summarized in Table 1. All 32 patients were evaluated for response and toxicity in the intent-to-treat analysis.

Adverse Reactions

Adverse reactions are summarized in Table 2. Main adverse reactions were hematological, gastrointestinal and cutaneous symptoms. Adverse reactions were observed in 31 patients whose percentage was 89% (95% CI: 78.0-99.1%). The severe adverse Grade 3 or 4 reactions were observed in 8 patients whose percentage was 23% (95% CI: 8.9-36.8%). All adverse reactions were reversible and there was no patient of treatment-related death.

Feasibility

The total number of treatment courses was 185 (median, 5 courses per patient; range, 1-15 courses). Total administration days of TS-1 in each patient were distributed from 6 to 210 days (median: 56 days). The cumulative rate of total administration days of TS-1

TABLE 2 Adverse Reactions

Adverse reaction	Grade (No. of patients)				Overall No. (%)	Grade 3 and 4 No. (%)
	1	2	3	4		
Hematological						
Leucopenia	8	2	0	0	10 (29%)	0
Neutropenia	3	4	2	0	9 (26%)	2 (6%)
Anemia	10	8	1	0	19 (54%)	1 (3%)
Thrombocytopenia	2	0	1	0	3 (9%)	1 (3%)
Non-hematological						
Nausea/vomiting	9	3	1	0	13 (37%)	1 (3%)
Anorexia	10	3	2	2	17 (49%)	4 (11%)
Diarrhea	5	1	0	0	6 (17%)	0
Stomatitis	7	0	0	2	9 (26%)	2 (6%)
Fatigue	2	1	1	0	4 (11%)	1 (3%)
Cutaneous symptoms	7	1	0	0	8 (23%)	0
Headache	0	1	0	0	1 (3%)	0
Abdominal pain	1	0	0	0	1 (3%)	0
Bilirubin	1	0	0	0	1 (3%)	0
Transaminase	0	0	1	0	1 (3%)	1 (3%)




FIGURE 1

Overall survival of the 35 patients. Cumulative rate of total administration days of TS-1 by Kaplan-Meier method.

TABLE 3 Feasibility

Median treatment courses (range)	5 courses (1-15)
Total number of treatment courses	185 courses
Median administration days (range)	56 days (6-210)
Total number of administration days	2505 days
Relative total administration days	93%
Rate of patients who received six or more courses	43%
Rate of patients in whom administration was halted due to	
Exacerbation of symptoms	74%
Adverse events	26%

until 210 days was calculated by the Kaplan-Meier method (Figure 1). The rate of patients who received six or more courses (equivalent to three or more courses of administration for 4 weeks followed by a 2-week rest) was 43% (15/35). The rates of patients in whom administration was halted due to exacerbation of symptoms and adverse events were 74% (26 patients) and 26% (9 patients), respectively. The total of treatment days involving both administration period and rest period in all patients was 4026 days. If there was any interruption of TS-1 administration due to adverse reactions, 2684 days (4026 days x 14/21) were planned as the total administration days of TS-1. Actual total administration days of TS-1 in this study was 2505 days. Therefore the cumulative rate of the

relative total administration days was 93% (2505/2684).

Efficacy

The responses of this study are summarized in Table 4. There were 6 PRs, 13 NCs, 11 PDs, and 5 patients were not evaluable (NE), yielding a response rate (RR) of 17% (6 of 35 patients; 95% CI, 7.2%-34.3%). The response rate of the patients with intestinal-type adenocarcinoma and diffuse-type adenocarcinoma were 16% and 19%, respectively. The response rate of the 33 patients without prior chemotherapy was 18% (6/33). The median response duration was 203 days (range, 53 to 235 days). The median survival time of all patients was 290 days (95% CI, 214-438) (Figure 1).

DISCUSSION

Combination chemotherapy, for example DCF combination therapy (Docetaxel/CDDP/5-FU), is the one of the standard for metastatic gastric cancer in USA from the results of large scale phase III study. However this combination chemotherapy is not easily acceptable in Japan because of its high toxicities and impossibility of outpatient chemotherapy. On the other hand, Japan Clinical Oncology Group (JCOG) regards continuous intravenous infusion of 5-FU as the reference arm at present and phase III study (JCOG-9912), which inspects the superiority of CPT11+CDDP or non-numerical inferiority of TS-1 compared with continuous intravenous infusion of 5-FU as the reference arm in survival, is on-going at present in Japan. However TS-1 monotherapy is already the most frequently used regimen for metastatic gastric cancer as a community standard therapy in Japan, because of its highest response rate as a single agent among all anticancer agents for metastatic gastric cancer and its convenience as an oral agent. Three phase III trials to inspect the superiority of TS-1 combined chemotherapy with CDDP (Taiho), CPT11 (Yakuruto and Daiichi), or Docetaxel (JACCRO) in survival compared with TS-1 monotherapy as a control arm are

already on-going at present in Japan. The conventional schedule of TS-1 monotherapy consists of administration of 80mg/m²/day for 4 weeks followed by a 2-week rest in one cycle and is repeated for as long as there is no exacerbation of symptoms or severe adverse events. This conventional schedule is also adopted in this clinical study described above.

However, the percentage of patients who received three or more courses was only 47% according to a postmarketing survey of TS-1 and TS-1 administration was halted in 33% of patients due to adverse reactions. This survey also reported that the median time to the worst toxic events was 22 days for hematological toxicities and 15 days for diarrhea and stomatitis. Therefore the new schedule of TS-1 monotherapy consisting of administration of 80mg/m²/day for 2 weeks followed by a 1-week rest was devised aiming at adverse reaction mitigation and prolonged medication. Kimura *et al.* suggested that this new schedule might mitigate adverse reactions and prolong the medication period compared with the conventional schedule for metastatic gastric cancer. However they also reported that a multicenter collaborative prospective study of this new schedule was necessary to confirm its superiority because their study involved retrospective analysis using historical controls in one institute without extramural review. Tsukuda *et al.* also reported that this new schedule seemed to be more tolerable and safer compared with the conventional schedule for adjuvant chemotherapy in advanced head and neck cancer. However, the type of cancer was different from ours and the subjects were patients receiving adjuvant chemotherapy without primary or metastatic lesion in this report. Therefore we conducted this phase II study to examine whether this new schedule might mitigate adverse reactions and prolong the medication period without decrease of its antitumor effect.

This study examined the safety and efficacy of the new schedule of TS-1. The ORR was 17% (95% CI, 7.2%-34.3%), which was the primary endpoint. Therefore, this new schedule of TS-1 administration is statistically active, but might reduce the antitumor effect compared with the conventional schedule of TS-1 administration for metastatic gastric cancer.

The incidence of adverse reactions was 89% (95% CI: 78.0x-99.1%) and that of adverse reactions at Grade 3 and 4 was 23% (95% CI: 8.9-36.8%). Judging from the fact that the incidence of adverse reactions was 78% and that of adverse reactions at Grade 3 and 4 was 20% according to a premarketing late phase II study adopting the conventional schedule of TS-1 administration, this new schedule of TS-1 administration might not reduce the toxicities compared with the conventional schedule of TS-1 administration for metastatic gastric cancer.

In this study, the rate of patients who received six or more courses (equivalent to three or more courses of the conventional schedule of TS-1) was 43% (15/35). Judging from the fact that the rate of patients who received three or more courses of the conventional schedule of TS-1 administration was 44.6% according

TABLE 4 Response

Patients	(n)	CR	PR	NC	PD	NE	RR
Overall	35	0	6	13	11	5	17%
Metastatic site							
Lymph node	16	0	4	7	3	2	25%
Liver	12	0	0	6	6	0	0%
Lung	3	1	1	0	0	1	67%
Peritoneum	5	0	0	0	2	3	0%
Others	2	0	1	1	0	0	50%
Primary site							
	8	0	1	4	2	1	13%
Histological type							
Intestinal	19	0	3	9	4	3	16%
Diffuse	16	0	3	4	7	2	19%
Prior chemotherapy							
Adjuvant	2	0	0	0	1	1	0%
No chemotherapy	33	0	6	13	10	4	18%

to a postmarketing survey, this new schedule of TS-1 administration might not unfortunately prolong medication compared with the conventional schedule of TS-1 administration for metastatic gastric cancer, nevertheless, the cumulative rate of the relative total administration days was 93% in this study.

The median survival time (MST) in our study was 290 days. Compared with 250 days (95% CI 171-376 days) reported in a premarketing late phase II study, this new schedule of TS-1 administration was acceptable from the point of survival view.

CONCLUSION

We concluded that the schedule of TS-1 adminis-

tration for 2 weeks followed by a 1-week rest might not be superior to the conventional schedule (4 weeks on and 2 weeks off) with regard to the antitumor effect, adverse reactions and prolonged medication, although it was acceptable from the viewpoint of survival. Further comparative study is needed for the evaluation of this new schedule (2 weeks on and 1 week off).

ACKNOWLEDGEMENTS

This work was supported in part by Grant-in-aid (17S-3) from the Ministry of Health, Labor, and Welfare Japan.

REFERENCES

- 1 Duschinsky R, Plevin E, Heidelberger C: The synthesis of 5-fluoropyrimidined. *J Am Chem Soc Anticancer* 1957; 79:4559-4560.
- 2 Caballero GA, Ausman RK, Quebbeman EJ: Long-term ambulatory continuous iv infusion of 5-FU for the treatment of advanced adenocarcinomas. *Cancer Treat Rep* 1985; 69:13-15.
- 3 Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, et al: Continuous 5-fluorouracil infusion in advanced gastric carcinoma. *Am J Clin Oncol* 1988; 11:461-464.
- 4 Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekuma K, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. *Anticancer Drugs* 1996; 7:548-557.
- 5 Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. *Jpn J Cancer Res* 1987; 78:743-755.
- 6 Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. *Cancer Res* 1993; 53:4004-4009.
- 7 Schoffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. *Anticancer Dugs* 2004; 15:85-106.
- 8 Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimes-tat-1M otastat potassium) in advanced gastric cancer patients. *Eur J Cancer* 1998; 34:1715-1720.
- 9 Sugimachi K, Haehara Y, Horikoshi N, Shimada Y, Sakata Y and Mitachi Y, et al: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. *Oncology* 1999; 57:202-210.
- 10 Nagashima F, Ohtsu A, Yoshida S, Ito K: Japanese nationwide postmarketing survey of S-1 in patients with advanced gastric cancer. *Gastric Cancer* 2005; 8:6-11.
- 11 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. *J Nat Cancer Inst* 2000; 92:205-216.

AUTHOR PLEASE CITE TABLE 3 IN THE TEXT AND PLEASE CITE REFERENCE 11

Adjuvant and Neoadjuvant Therapy of Gastric Cancer: A Comparison of Three Pivotal Studies

Takeshi Sano, MD

Corresponding author

Takeshi Sano, MD
Gastric Surgery Division, National Cancer Center Hospital,
5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
E-mail: tksano@ncc.go.jp

Current Oncology Reports 2008, **10**:191-198
Current Medicine Group LLC ISSN 1523-3790
Copyright © 2008 by Current Medicine Group LLC

In the past, the role of adjuvant therapy for gastric cancer was indefinite. However, three large, randomized controlled trials have recently shown the survival benefit of adjuvant therapy over surgery alone: the American INT 0116 trial, with adjuvant chemoradiation therapy; the European MAGIC trial, with perioperative combination chemotherapy; and the Japanese ACTS-GC trial, with adjuvant monotherapy. Because the patient populations and surgical approaches are considerably different among these trials, it is not sensible to simply compare survival rates to determine the best modality. In the time since these pivotal trials, various innovative studies have been planned and launched to evaluate treatment factors including modality (chemotherapy or chemoradiation), timing (before and/or after surgery), and different surgical extent (D1 or D2 lymphadenectomy). Because the East and West have different backgrounds and treatments for localized gastric cancer, each region should design its own clinical trial to determine the best evidence-based treatment regimens.

Introduction

Adjuvant therapy aims to improve survival by eliminating residual micrometastatic disease after curative resection of solid tumors. Gastric cancer has long been a focus of adjuvant studies; however, numerous past trials failed to prove the benefit of adjuvant therapy. Although some meta-analyses showed statistically significant superiority of adjuvant chemotherapy, they could not provide clinically significant conclusions due to the heterogeneity in therapeutic regimens, disease stages, and quality of surgery among the studied trials [1,2]; all phase 3 trials

thus needed a control arm of surgery alone to produce evidence. The absence of a pivotal trial in adjuvant therapy for gastric cancer could be attributed to two reasons: 1) the absence of powerful treatment regimens to improve survival, and 2) the difficulty in conducting a large-scale, randomized controlled trial with sufficient statistical power for this disease.

Recently, three different modalities of adjuvant therapy for localized gastric cancer were proven to improve survival in three large-scale, randomized controlled trials conducted in three different regions in the world. These trials, the SWOG 9008/INT 0116 trial (INT 0116) of adjuvant chemoradiation in the United States [3], the MAGIC trial of perioperative three-agent chemotherapy in Europe [4••], and the ACTS-GC trial of adjuvant S-1 monotherapy in Japan [5••] have led to a new phase in this field of study.

Because these studies have different patient populations and surgical approaches, cross-trial comparisons of the survival results are not easy. In this review, these trials are carefully compared with special reference to the patient selection and the role of surgery. Currently active clinical trials and future directions are also discussed.

Overview of the Three Trials

The INT 0116 trial

The eligibility criteria for the INT 0116 study included stage IB through IV M0 adenocarcinoma of the stomach or gastroesophageal junction, with registration occurring 20 to 41 days after complete resection with free resection-line involvement. Of the 603 patients registered between 1991 and 1998, 556 were eligible and randomly assigned to surgery only ($n = 275$) or to surgery plus chemoradiotherapy ($n = 281$). The adjuvant regimen consisted of 5-fluorouracil (5-FU) (425 mg/m^2) plus leucovorin (20 mg/m^2) for 5 days, followed by a total of 45-Gy radiation given for 5 weeks with modified doses of 5-FU/leucovorin, and two 5-day cycles of 5-FU (425 mg/m^2) plus leucovorin (20 mg/m^2). Chemoradiotherapy was completed as planned in 64% of patients; it was stopped in 25% because of toxic effects or patient declination. Three patients (1%) died of toxic effects.

More than half the tumors were located in the antrum, and about 20% were in the cardia. Sixty-nine percent of the tumors were T3 or T4, and 85% had nodal metastases. The review of the surgical records of 552 patients showed that, although the study protocol had recommended D2 lymphadenectomy, the majority underwent limited resection (54% D0, 36% D1, 10% D2). With a median follow-up of 5 years, the median survival time and the 3-year survival rates of the surgery and surgery-plus-chemoradiation groups were 27 months (41%) and 36 months (50%), respectively. The first site of recurrence was more local-regional in the surgery-only group than in the adjuvant group.

The MAGIC trial

The eligibility criteria for the MAGIC trial included stage II or higher M0 adenocarcinoma of the stomach or lower third of the esophagus that was deemed resectable. Between 1994 and 2002, 503 patients were randomly assigned to surgery alone ($n = 253$) or to perioperative chemotherapy and surgery ($n = 250$). The chemotherapy consisted of three preoperative and three postoperative cycles of ECF: epirubicin (50 mg/m²) plus cisplatin (60 mg/m²) on day 1 and a continuous intravenous infusion of 5-FU (200 mg/m²) for 21 days. Of the 237 patients who started preoperative chemotherapy, 215 (90.7%) completed it, and 209 of this subset proceeded to surgery. Postoperative chemotherapy was started in 137 patients and was completed in 104 patients (41.6% of the chemotherapy group).

Surgery was performed in 91.6% of the chemotherapy group and in 96.4% of the surgery group. Resection was curative in 69.3% of the chemotherapy group and 66.4% of the surgery group. The extent of lymphadenectomy was not specified in the protocol and was decided by the surgeon. The postoperative mortality rates were similar between the two groups (5.6% and 5.9%). In the surgery group, 63.2% of tumors were T3 or T4, and 73.1% had lymph node metastases. In the chemotherapy group, the tumor diameter was smaller, the proportion of T1 and T2 was greater, and the proportion of N0 and N1 was greater than in the surgery group, suggesting the downstaging effect of preoperative chemotherapy.

With a median follow-up of 47 to 49 months, the overall and progression-free survival rates in the chemotherapy group were significantly better than those in the surgery group. The 5-year survival rates were 36.3% in the chemotherapy group and 23.0% in the surgery group. Both local and distant recurrences were more frequently seen in the surgery group.

The ACTS-GC trial

The eligibility criteria for the ACTS-GC trial included stage II (excluding T1), IIIA, or IIIB adenocarcinoma of the stomach, after D2 or more extensive curative surgery, with no tumor cells in the peritoneal lavage cytology; patients were also no older than 80 years of age.

Between 2001 and 2004, 1059 patients were registered from 109 high-volume hospitals in Japan and were randomly assigned to surgery only ($n = 530$) or to adjuvant chemotherapy ($n = 529$). The chemotherapy consisted of 6-week cycles of S-1 (an orally active fluoropyrimidine [6–8]; 80 mg/m² for 4 weeks followed by 2-week rest) for 1 year starting within 6 weeks postoperatively. This regimen was continued for at least 3 months in 87.4% of patients, for 6 months in 70.8%, and for 12 months in 65.8%. Dose modification due to toxicity was necessary in 42.4% of patients. The tumors were predominantly located in the distal stomach; 58% were treated by distal gastrectomy. Forty-six percent of the tumors were T3 or T4, and 89% had lymph node metastasis.

The study was designed to compare the 5-year overall survival, but the first interim analysis with a median follow-up of 2 years showed a significant difference in overall and relapse-free survival in favor of the chemotherapy group, and the trial was discontinued. In the published data, with a median follow-up of 2.9 years, the 3-year overall survival rates were 80.1% in the chemotherapy group and 70.1% in the surgery group. Fewer relapses in peritoneum and lymph nodes were observed in the chemotherapy group. Subgroup analyses showed no interaction between any studied variables.

Comparison of the Three Trials

Patient population

Curability

The patient population was essentially different between the MAGIC trial and the other two trials. MAGIC recruited cases deemed to be resectable, whereas the other two studies included only patients after curative gastrectomy. It has been well established that R0 resection without gross or microscopic residual disease is one of the most important prognostic determinants of gastric cancer [9,10].

Curability of gastric cancer without apparent distant metastasis largely depends on peritoneal dissemination. Staging laparoscopy with biopsy is the only method available to diagnose this before definitive surgery. In the MAGIC trial, laparoscopy was listed as a staging method but did not seem to have been employed in many patients: in 28% of the patients assigned to the surgery group, the operation turned out to be noncurative at laparotomy, and half of these individuals underwent nonresectional surgery.

Contamination of noncurative cases is inevitable in neoadjuvant trials but should be avoided with every effort. It is especially important to exclude individuals with peritoneal metastasis that is most refractory to chemotherapy. In current ongoing trials for neoadjuvant therapy, staging laparoscopy is usually mandatory to exclude peritoneal disease and is useful to select patients who may truly benefit from the treatment [11•].